Loading...

Pediatric Approvals And Asian Expansion Will Unlock Future Markets

Published
11 Dec 24
Updated
23 Aug 25
AnalystConsensusTarget's Fair Value
DKK 193.00
6.4% overvalued intrinsic discount
04 Sep
DKK 205.40
Loading
1Y
15.8%
7D
1.1%

Author's Valuation

DKK 193.0

6.4% overvalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on23 Aug 25
Fair value Increased 6.63%

The increase in ALK-Abelló’s analyst price target is primarily driven by a modest upward revision in consensus revenue growth forecasts, while net profit margins remain steady, resulting in a new fair value estimate of DKK192.33 per share. What's in the News ALK-Abelló raised its 2025 revenue growth guidance to 12-14% (from 9-13%) in local currencies, supported by strong adrenaline autoinjector and tablet sales in Europe and North America, and will allocate additional funds to strategic growth investments.

Shared on01 May 25
Fair value Decreased 3.05%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 3.09%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Decreased 0.64%

AnalystConsensusTarget has increased revenue growth from 11.5% to 12.7% and decreased profit margin from 23.6% to 19.8%.